Profound Medical (PROF) Projected to Release Earnings on Thursday

Profound Medical (NASDAQ:PROF) is expected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1920) per share and revenue of $8.82 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.04). The company had revenue of $2.48 million during the quarter, compared to the consensus estimate of $4.75 million. Profound Medical had a negative return on equity of 63.03% and a negative net margin of 171.57%. On average, analysts expect Profound Medical to post ($0.79) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

Profound Medical Trading Up 2.2%

Profound Medical stock traded up $0.14 during trading hours on Tuesday, hitting $6.88. 23,731 shares of the stock traded hands, compared to its average volume of 168,771. The firm’s 50-day moving average price is $6.22 and its two-hundred day moving average price is $6.68. The company has a market cap of $251.36 million, a PE ratio of -7.01 and a beta of 0.75. Profound Medical has a one year low of $4.80 and a one year high of $8.95.

Wall Street Analyst Weigh In

PROF has been the subject of a number of research analyst reports. Weiss Ratings cut Profound Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. Raymond James Financial raised Profound Medical from an “outperform” rating to a “strong-buy” rating and set a $11.00 price target on the stock in a research note on Monday, July 27th. Finally, Wall Street Zen upgraded Profound Medical from a “sell” rating to a “hold” rating in a report on Saturday, October 10th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.50.

About Profound Medical

Profound Medical Corp. is a medical-technology company focused on developing and commercializing minimally invasive, incision-free treatments for prostate disease. The company’s flagship platform, TULSA-PRO, combines magnetic resonance imaging (MRI) with robotic-controlled transurethral ultrasound to ablate targeted prostate tissue while enabling physicians to monitor treatment in real time.

TULSA-PRO is primarily used for the treatment of localized prostate cancer and other prostate conditions, including benign prostatic hyperplasia.